Vibativ back on track in US; new adventures ahead for Theravance
This article was originally published in Scrip
Executive Summary
With the help of its new manufacturing partner Hospira, Theravance's injectable antibiotic Vibativ (telavancin) is back on the US market, with the firm declaring on 14 August it has re-established distribution of the medicine after a nearly two-year hiatus, which was triggered because of compliance issues with its former supplier.